Navigation Links
United Therapeutics Announces Decision From Patent Trial And Appeal Board And Issuance Of New Patents
Date:3/31/2017

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., March 31, 2017 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced that the U.S. Patent and Trademark's Office (USPTO) Patent Trial and Appeal Board (PTAB) issued a Final Written Decision in connection with the inter partes review (IPR) of United Therapeutics' U.S. Patent No. 8,497,393 (the '393 patent). The PTAB found that all claims of the '393 patent are not patentable. United Therapeutics is evaluating its options, including the possibility of immediately exercising its right of appeal to the U.S. Court of Appeals for the Federal Circuit or first requesting a rehearing before the PTAB. The '393 patent remains valid and enforceable until appeals have been exhausted.

By way of background, the '393 patent claims, among other things, treprostinil produced using an improved method and is listed in FDA's Approved Drug Products with Therapeutic Equivalence Evaluations publication, also known as the Orange Book, for Remodulin® (treprostinil) Injection, Tyvaso® (treprostinil) Inhalation Solution, and Orenitram® (treprostinil) Extended-Release Tablets. United Therapeutics is currently asserting the '393 patent (along with several other patents) against Watson Laboratories, Inc. and Actavis Laboratories FL, Inc. in connection with their efforts to obtain approval to market generic copies of Tyvaso and Orenitram, respectively. The Watson and Actavis cases are scheduled for trial in September 2017 and February 2018, respectively. SteadyMed, Ltd. initiated the IPR in October 2015, and has reported plans to file for FDA approval of its Trevyent® treprostinil product in the second quarter of 2017.

United Therapeutics intends to continue vigorously defending the '393 patent, but even if the ultimate result is unfavorable, United Therapeutics has other patents claiming subject matter similar to the '393 patent and with the same expiration date (December 2028). Specifically, in the last month, the USPTO awarded United Therapeutics two additional patents related to the '393 patent, U.S. Patent Nos. 9,593,066 and 9,604,901. United Therapeutics prosecuted the applications that resulted in these new patents in parallel with the '393 patent IPR and presented claims addressing the invalidity arguments raised by SteadyMed in the IPR and Watson and Actavis in the ongoing litigations. The USPTO allowed the new patent claims with full knowledge of the IPR, the invalidity arguments presented therein, and the invalidity arguments raised by Watson and Actavis in connection with the '393 patent. Thus, United Therapeutics anticipates that these new patents should be less susceptible to challenge than the '393 patent. United Therapeutics has listed both these new patents in the Orange Book for Remodulin, Tyvaso, and Orenitram.     

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. [uthr-g]

Forward-looking Statements

Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements regarding the possibility of United Therapeutics appealing the PTAB decision, United Therapeutics' intent to continue vigorously defending the '393 patent, United Therapeutics' belief that the two newly issued patents should be less susceptible to challenge than the '393 patent, and the impact of the two newly-issued patents on the timing of market entry for Trevyent. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic and other reports filed with the Securities and Exchange Commission that could cause actual results to differ materially from anticipated results. These risks and uncertainties include, among others, United Therapeutics' plans and ability to defend its intellectual property against challenges from generic companies and from SteadyMed, and such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of March 31, 2017, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/united-therapeutics-announces-decision-from-patent-trial-and-appeal-board-and-issuance-of-new-patents-300432711.html


'/>"/>
SOURCE United Therapeutics Corporation
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Entia Receives Notices of Allowance for its Ergothioneine and Genetic Transporter Patents from the United States, Canada, and Israel
2. National Honey Board Seeks Board Member Nominees: Appointments to be Made by United States Secretary of Agriculture
3. United Therapeutics Corporation To Announce First Quarter 2013 Financial Results Before Market Open On Thursday, April 25, 2013
4. SoundConnect Announces Lync Release in the United States
5. Atlantic Peptides Teams Up with a United Kingdom Company to Offer cGMP Peptides and API
6. Despite Lucentiss Recent Expanded Label for Diabetic Macular Edema, Avastin Remains the Preferred Intravitreal Therapy for Diabetic Macular Edema in the United States
7. United Airlines and AltAir Fuels to Bring Commercial-Scale, Cost-Competitive Biofuels to Aviation Industry
8. SPIE on Global Team Proposing ‘international Year of Light’ at United Nations
9. Prevagen® is the Number One Branded Memory Supplement in the United States
10. Centre for Sight First in the United Kingdom to Utilize TrueVision® 3D Visualization During Femtosecond Laser Cataract Surgery
11. Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2019)... , ... September 03, 2019 ... ... of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene ... Science & Technology will present at the upcoming Nordic Life Science Days ...
(Date:8/27/2019)... ... 27, 2019 , ... Dr. Kim Carlson is a veterinary surgeon practicing in ... Surgical Group , a new surgical practice in San Mateo. She is currently ... more veterinary specialists as the practice grows. , When asked about the opening of ...
(Date:8/15/2019)... (PRWEB) , ... August 15, 2019 , ... ... Scientific Advisory Board. Mr. Lawrence is a member of the Institute of Food ... Safety and Health (IFSH) Advisory Board, Joint Institute for Food Safety and Applied ...
(Date:8/6/2019)... ... August 06, 2019 , ... The San Diego Biotechnology ... the biweekly SDBN BUZZ podcast focused on connecting the region’s biotech community and ... to promote the region and attract external employers, investors, scientists, and others who ...
Breaking Biology Technology:
(Date:8/29/2019)... ... , ... Lajollacooks4u has expanded its team as it gears up for a ... seen record growth in 2019, having hosted a multitude of team-building events and cooking ... visited the company’s La Jolla-based venue, and Lajollacooks4u has worked hard to accommodate the ...
(Date:8/27/2019)... Fla. (PRWEB) , ... August 27, 2019 , ... ... in life science and drug development. This episode is scheduled to broadcast 4Q/2019. ... explore Debiopharm, a biopharmaceutical research, development, investment and manufacturing company. The show will ...
(Date:8/21/2019)... ... August 20, 2019 , ... Cutting Edge ... for the spine, today announced the 510(K) clearance of its novel SI joint ... is proven to improve osseointegration through superior hydrophilicity and optimized surface chemistry, as ...
Breaking Biology News(10 mins):